Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis

Xinfang Xie(Peking University), Anthony Rodgers(The George Institute for Global Health), Kazem Rahimi(University of Oxford), Alexander Bennett(The George Institute for Global Health), Stephen MacMahon, Vlado Perkovic(New South Wales Department of Health), Mark Woodward(UNSW Sydney), Jonathan Mant(University of Cambridge), John Chalmers(UNSW Sydney), Jicheng Lv(Ministry of Education of the People's Republic of China), Bruce Neal(UNSW Sydney), Toshiharu Ninomiya(Kyushu University), Abdul Salam(University of Sydney), Graham S. Hillis(The University of Western Australia), Fiona Turnbull(University of Sydney), Emily Atkins(University of Sydney)
The Lancet
November 7, 2015
10.1016/s0140-6736(15)00805-3
Cited by 984

Related Papers

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k